2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3148

Physical Activity in Children and Adolescents with Juvenile Idiopathic Arthritis and Associated Factors
Abstract Number: 512

Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?
Abstract Number: 2457

Physical Function and Psychological Well-Being in Teens with Juvenile Idiopathic Arthritis (JIA): Characterization and Exploration of Technology-Assisted Self-Management
Abstract Number: 2681

Physical Function, Sleep, Depression but Not CRP Level Is Associated with Fatigue in Patients with Established Rheumatoid Arthritis
Abstract Number: 2272

Physical Performance Contributes Only Marginally in Explaining Fatigue Variation in Persons with RA Moderately Affected By Their Disease
Abstract Number: 136

Physician Patterns of Patient Care in Systemic Lupus Erythematosus: Are We Ordering Unnecessary Tests?
Abstract Number: 1445

Physicians’ Perspectives on the Diagnosis and Treatment of Chronic Nonbacterial Osteomyelitis
Abstract Number: 1251

Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Abstract Number: 2121

Placentas of Lupus Pregnancies Are Characterized By Marked Inflammatory Changes Despite Good Disease Control
Abstract Number: 1572

Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors
Abstract Number: 524

Plasma Concentrations of Antibodies to Porphyromonas Gingivalis Are Increased before Onset of Symptom of Rheumatoid Arthritis
Abstract Number: 1992

Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 888

Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study
Abstract Number: 532

Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression: Preliminary Results
Abstract Number: 309

Plasma Levels of Heat Shock Protein 90 Are Increased in Idiopathic Inflammatory Myopathies and Correlate with Disease Activity, Skeletal Muscle, Heart and Lung Involvement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].